|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM361969406 |
| 003 |
DE-627 |
| 005 |
20240114234226.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202305361
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1257.xml
|
| 035 |
|
|
|a (DE-627)NLM361969406
|
| 035 |
|
|
|a (NLM)37699593
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhou, Liqiang
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Immunogenic PANoptosis-Initiated Cancer Sono-Immune Reediting Nanotherapy by Iteratively Boosting Cancer Immunity Cycle
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.01.2024
|
| 500 |
|
|
|a Date Revised 12.01.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a The cancer-immune cycle conceptualized the mechanisms of driving T cell responses to tumors, but w as limited by immunological ignorance elicited by tumor inherent immunoediting, which failed to initiate and maintain adaptive immunity. Targeting specific vulnerabilities of cell death patterns may provide unique opportunities to boost T cell antitumor immunological effects. Here an ultrasound nanomedicine-triggered tumor immuno-reediting therapeutic strategy using nano/genetically engineered extracellular vesicles, which can induce tumor highly immunogenic PANoptosis and iteratively start-up the energization of cancer innate immunity cycle by repeatedly liberating damage-associated molecular patterns, thereby priming sufficient antigen-specific T cells and shaping protective immune response through activating cGAS-STING signaling pathways, is reported. Aided by immune checkpoint blockade, the reprogramming of immune microenvironment further facilitated a prompt bridging of innate and adaptive immunity, and remarkably suppressed metastatic and rechallenged tumor growth. Thus, targeting PANoptotic cell death provides a catcher against immune escape and a positive-feedback immune activation gateway for overcoming immune resistance to intractable cancers
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a PANoptosis
|
| 650 |
|
4 |
|a engineered extracellular vesicles
|
| 650 |
|
4 |
|a immune regulation
|
| 650 |
|
4 |
|a regulated cell death
|
| 650 |
|
4 |
|a ultrasound immune-reediting
|
| 650 |
|
7 |
|a Antigens, Neoplasm
|2 NLM
|
| 700 |
1 |
|
|a Lyu, Jinxiao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Fang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Su, Yanhong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Feng, Ling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Xuanjun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 2 vom: 11. Jan., Seite e2305361
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:2
|g day:11
|g month:01
|g pages:e2305361
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202305361
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 2
|b 11
|c 01
|h e2305361
|